메뉴 건너뛰기




Volumn 32, Issue 8, 2007, Pages 699-702

ISIS-301012: Antisense inhibitor of apolipoprotein B treatment of lipoprotein disorders

(1)  Wang, Y a  


Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; ATORVASTATIN; EZETIMIBE; ISIS 301012; LOW DENSITY LIPOPROTEIN; PLACEBO; SIMVASTATIN; UNCLASSIFIED DRUG;

EID: 35649007736     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.08.1132978     Document Type: Article
Times cited : (2)

References (15)
  • 1
    • 35648968328 scopus 로고    scopus 로고
    • Accessed July 9, 2007
    • http://www.americanheart.org. Accessed July 9, 2007.
  • 2
    • 33750207033 scopus 로고    scopus 로고
    • Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
    • Kastelein, J., Wedel, M., Baker, B. et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006, 114(16): 1729-35.
    • (2006) Circulation , vol.114 , Issue.16 , pp. 1729-1735
    • Kastelein, J.1    Wedel, M.2    Baker, B.3
  • 3
    • 0033827087 scopus 로고    scopus 로고
    • Apolipoprotein B: MRNA editing, lipoprotein assembly, and presecretory degradation
    • Davidson, N.O., Shelness, G.S. Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000, 20: 169-93.
    • (2000) Annu Rev Nutr , vol.20 , pp. 169-193
    • Davidson, N.O.1    Shelness, G.S.2
  • 4
    • 33847338002 scopus 로고    scopus 로고
    • Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100
    • Yu, R., Kim, T.-W., Hong, A., Watanabe, T.A., Gaus, H.J., Geary, R.S. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 2007, 35(3): 460-8.
    • (2007) Drug Metab Dispos , vol.35 , Issue.3 , pp. 460-468
    • Yu, R.1    Kim, T.-W.2    Hong, A.3    Watanabe, T.A.4    Gaus, H.J.5    Geary, R.S.6
  • 5
    • 35648940976 scopus 로고    scopus 로고
    • Graham, M.J., Lemonidis, K.M., Whipple, C., Petinos, N., Crooke, R.M. Inhibition of human apoB-100 in transgenic mice. Circulation [76th Am Heart Assoc Sci Sess (Nov 9-12, Orlando) 2003] 2003, 108(17, Suppl. 4): Abst 836.
    • Graham, M.J., Lemonidis, K.M., Whipple, C., Petinos, N., Crooke, R.M. Inhibition of human apoB-100 in transgenic mice. Circulation [76th Am Heart Assoc Sci Sess (Nov 9-12, Orlando) 2003] 2003, 108(17, Suppl. 4): Abst 836.
  • 6
    • 33750028350 scopus 로고    scopus 로고
    • A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient mice expressing a human apoB-100 transgene
    • June 18-22, Rome, Abst Th-W49
    • Chuang, E., Lemonidis, K.M., Whipple, C., Graham, M.J., York-Defalco, C., Hung, G., Crooke, R.M. A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient mice expressing a human apoB-100 transgene. Atherosclerosis Suppl [14th Int Symp Atherosclerosis (June 18-22, Rome) 2006] 2006, 7(3): Abst Th-W49:5.
    • (2006) Atherosclerosis Suppl [14th Int Symp Atherosclerosis , vol.7 , Issue.3 , pp. 5
    • Chuang, E.1    Lemonidis, K.M.2    Whipple, C.3    Graham, M.J.4    York-Defalco, C.5    Hung, G.6    Crooke, R.M.7
  • 7
    • 35649023932 scopus 로고    scopus 로고
    • A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient, human apolipoprotein B-100 transgenic mice
    • April 27-29, Denver, Abst 2
    • Lemonidis, K.M., Whipple, C.P., Graham, M.J., Suramaniam, A., York-Defalco, C., Hung, G., Crooke, R.M. A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient, human apolipoprotein B-100 transgenic mice. 7th Annu Conf Arterioscler Thromb Vasc Biol (April 27-29, Denver) 2006, Abst 2.
    • (2006) 7th Annu Conf Arterioscler Thromb Vasc Biol
    • Lemonidis, K.M.1    Whipple, C.P.2    Graham, M.J.3    Suramaniam, A.4    York-Defalco, C.5    Hung, G.6    Crooke, R.M.7
  • 8
    • 35648950188 scopus 로고    scopus 로고
    • Cross-species pharmacokinetic comparison from mouse to man of a second generation antisense oligonucleotide ISIS 301012, targeting human apoB-100
    • Nov 6-10, Nashville, Abst T3306
    • Yu, R., Geary, R., Kim, T.-W., Cheung, E., Levin, A. Cross-species pharmacokinetic comparison from mouse to man of a second generation antisense oligonucleotide ISIS 301012, targeting human apoB-100. Annu Meet Am Assoc Pharm Sci (AAPS) (Nov 6-10, Nashville) 2005, Abst T3306.
    • (2005) Annu Meet Am Assoc Pharm Sci (AAPS)
    • Yu, R.1    Geary, R.2    Kim, T.-W.3    Cheung, E.4    Levin, A.5
  • 9
    • 84878727268 scopus 로고    scopus 로고
    • Pharmacokinetics and tolerability of daily oral antisense oligonucleotide, ISIS 301212, in mice and dog for 13 weeks
    • Nov 6-10, Nashville, Abst T3305
    • Geary, R., Yu, R., Kim, T.-W., Levin, A., Dokka, S., Tillman, L., Hardee, G. Pharmacokinetics and tolerability of daily oral antisense oligonucleotide, ISIS 301212, in mice and dog for 13 weeks. Annu Meet Am Assoc Pharm Sci (AAPS) (Nov 6-10, Nashville) 2005, Abst T3305.
    • (2005) Annu Meet Am Assoc Pharm Sci (AAPS)
    • Geary, R.1    Yu, R.2    Kim, T.-W.3    Levin, A.4    Dokka, S.5    Tillman, L.6    Hardee, G.7
  • 10
    • 35648947573 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic (PK/PD) modeling and dose regimen simulations to guide dose selection in phase 2a of an antisense oligonucleotide, targeting human apoB, in hypercholesterolemia subjects
    • Sept 17-19, Cambridge, Abst 33
    • Yu, R.Z., Geary, R.S., Bradley, J., Chuang, E., Wedel, M., Fuhr, R. Pharmacokinetic/pharmacodynamic (PK/PD) modeling and dose regimen simulations to guide dose selection in phase 2a of an antisense oligonucleotide, targeting human apoB, in hypercholesterolemia subjects. 35th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 17-19, Cambridge), 2006, Abst 33.
    • (2006) 35th Annu Meet Am Coll Clin Pharmacol (ACCP)
    • Yu, R.Z.1    Geary, R.S.2    Bradley, J.3    Chuang, E.4    Wedel, M.5    Fuhr, R.6
  • 11
    • 33750015093 scopus 로고    scopus 로고
    • Significant reduction of small dense LDL-cholesterol concentrations in healthy volunteers by antisense inhibition of apolipoprotein B
    • June 18-22, Rome, Abst Th-W49
    • Kastelein, J., Wedel, M.K., Baker, B., Su, J., Bradley, J., Chuang, E. Significant reduction of small dense LDL-cholesterol concentrations in healthy volunteers by antisense inhibition of apolipoprotein B. Atherosclerosis Suppl [14th Int Symp Atherosclerosis (June 18-22, Rome) 2006] 2006, 7(3): Abst Th-W49:6.
    • (2006) Atherosclerosis Suppl [14th Int Symp Atherosclerosis , vol.7 , Issue.3 , pp. 6
    • Kastelein, J.1    Wedel, M.K.2    Baker, B.3    Su, J.4    Bradley, J.5    Chuang, E.6
  • 12
    • 35648965420 scopus 로고    scopus 로고
    • Bradley, J., Crooke, R., Graham, M., Wedel, M. Small, dense, LDL particle concentration is significantly reduced after treatment with an antisense inhibitor of apoB in healthy volunteers. Circulation [78th Am Heart Assoc Sci Sess (Nov 13-16, Dallas) 2005] 2005, 112(17, Suppl. 2): Abst 727.
    • Bradley, J., Crooke, R., Graham, M., Wedel, M. Small, dense, LDL particle concentration is significantly reduced after treatment with an antisense inhibitor of apoB in healthy volunteers. Circulation [78th Am Heart Assoc Sci Sess (Nov 13-16, Dallas) 2005] 2005, 112(17, Suppl. 2): Abst 727.
  • 13
    • 33750022698 scopus 로고    scopus 로고
    • Hypolipidemic effects of a novel inhibitor of human apoB-100 in humans
    • June 10-14, San Diego, Abst 977-P
    • Bradley, J., Crooke, R., Kjems, L.L. et al. Hypolipidemic effects of a novel inhibitor of human apoB-100 in humans. 65th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 10-14, San Diego) 2005, Abst 977-P.
    • (2005) 65th Annu Meet Sci Sess Am Diabetes Assoc (ADA)
    • Bradley, J.1    Crooke, R.2    Kjems, L.L.3
  • 15
    • 33750002079 scopus 로고    scopus 로고
    • Effect of dose and dose schedule on the efficacy and safety of an antisense inhibitor of apoB in volunteers with mild hypercholesterolemia
    • June 18-22, Rome, Abst Th-P16
    • Kastelein, J.J.P., Bradley, J., Chuang, E., Wedel, M.W., Su, J., Geary, R., Yu, R. Effect of dose and dose schedule on the efficacy and safety of an antisense inhibitor of apoB in volunteers with mild hypercholesterolemia. Atherosclerosis Suppl [14th Int Symp Atherosclerosis (June 18-22, Rome) 2006] 2006, 7(3): Abst Th-P16:268.
    • (2006) Atherosclerosis Suppl [14th Int Symp Atherosclerosis , vol.7 , Issue.3 , pp. 268
    • Kastelein, J.J.P.1    Bradley, J.2    Chuang, E.3    Wedel, M.W.4    Su, J.5    Geary, R.6    Yu, R.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.